Kaare Engkilde, Ph.D., CEO
Lund, Sweden
Amniotics™ was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Center and Hospital, the company is pioneering the harvesting and propagation of tissue relevant neonatal quality mesenchymal stem cells (MSCs). Researchers and founders of the company, pediatrician Marcus Larsson, obstetrician Andreas Herbst, and stem cell specialist Niels-Bjarne Woods, discovered a new type of stem cells in amniotic fluid that has unique properties for applications in regenerative medicine. The company raised SEK 25M in 2020 to validate MSCs in preclinical models for lung disease as well as for the completion and process validation of the GMP manufacturing facility. With the new GMP facilities approved in October 2020, Amniotics is now looking to establish strategic partnerships with companies that are interested in developing stem cell-based therapies targeting diseases with unmet needs.

By using this website you agree to accept our Privacy Policy and Terms & Conditions